Tag: Boehringer Ingelheim

Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for.

Eli Lilly and BI to Focus Combined Expertise and Investment to Maximise Jardiance®

In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company will modernise their current alliance as of 1 January 2020 and focus its combined expe...

Boehringer Ingelheim Announced Partnership with The Defeat-NCD Partnership

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced its partnership with The Defeat-NCD Partnership, a public-private partnership anchored in the United Nations system...

Boehringer Ingelheim Expanded Plant in Georgia for $76m

Boehringer Ingelheim, a leading provider of animal health products for pets and livestock, marked the completion of work after a $76 million investment in its site in Athens, Ga. The investment double...

FDA Granted Breakthrough Therapy Designation to BI’s Ofev®

boehringer
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Ofev® (nintedanib), which is currently under FDA review for the treatment of...

BI Announced Positive Results of Phase III INBUILD® Trial Ofev®

boehringer
Boehringer Ingelheim announced that in Phase III INBUILD® trial Ofev® (nintedanib) slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline in...

BI to Donate 60k Doses of Rabies Vaccine for Dogs to Puerto Rico

boehringer
Boehringer Ingelheim, a global leader in veterinary rabies vaccines, plans to donate 60,000 doses of its IMRAB® rabies vaccine for dogs over the next three years to fight rabies in Puerto Rico. The...

BI and Inflammasome Entered into Co-Development and License Agreement

Boehringer Ingelheim and Inflammasome Therapeutics Inc. announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By ...

BI, Eli Lilly, Sanofi, Servier Develop Drug-Drug Interaction Risk Calculator

Elsevier, an information analytics business, is working together with a set of evaluation partners including Boehringer Ingelheim, Eli Lilly, Pierre Fabre, Sanofi, Servier, and others to develop a new...

FDA Approved Boehringer Ingelheim’s Ofev

boehringer
The U.S. Food and Drug Administration approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis ...

BI Announce $700m Deal for Lupin’s MEK Inhibitor Compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794. The p...

BI & MD Anderson Form Research and Development Center

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center(link is external) announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for v...

Boehringer Ingelheim Updated Real-World Data on Gilotrif

Boehringer Ingelheim announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of alm...

Boehringer Ingelheim Published Half-Year Results

boehringer ingelheim
In the first half of 2019, the research-driven pharmaceutical company Boehringer Ingelheim achieved further progress in research and development. In developing medicines, new approaches, and therapies...

FDA’s Arthritis Advisory Committee Recommended to Approve BI’s Ofev®

boehringer
Boehringer Ingelheim announced that the FDA’s Arthritis Advisory Committee recommended (10-7 vote) tor approve Ofev® (nintedanib) for the treatment of systemic sclerosis associated interstitial lung d...

BI and Bridge Biotherapeutics in New Collaboration and License Agreement

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxi...

Boehringer Ingelheim Announced Acquisition of AMAL Therapeutics

boehringer
Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic can...